Clinical Need & Applications
According to a world-renowned breast cancer surgeon at a Boston hospital, "Clean margins are the number one issue for breast cancer surgery and breast conserving lumpectomies."
Balancing the need to ensure you’ve removed cancerous tissue and tumor margins while preserving precious tissue is a perpetual challenge. Despite standardization of negative margin definition, applications of new technologies, and promising new surgical techniques, there remains a significant unmet need for surgeons and patients to reduce the rate of second surgeries due to cancer cells left behind during surgery.
“Re-excision rates among women with close or positive margins range from less than 10% to more than 50%, and the burdens of reoperation (cosmetic, emotional, and financial) are considerable.” [NEJM 2015]
The Lumicell System combines an investigational onco-fluorescent agent (LUM015) and handheld imaging device that together are designed to enable surgeons to see residual cancer cells in the cavity walls in real-time during surgery. The Lumicell System is designed to help surgeons remove cancer cells while sparing healthy tissue, increasing physician and patient confidence in surgical and cosmetic outcomes.
Lumicell System is also under investigation for ovarian cancer, prostate cancer, brain cancer, colorectal, esophageal and pancreatic cancers.
CAUTION – New Drug and Investigational device. Limited by Federal (or United States) law to investigational use.